 |
인쇄하기
취소
|
Daewon to launch new anti-inflammatory drug in October
Daewon Pharm plans to launch its new nonsteroidal anti-inflammatory drug, Peluvi tablets (felubiprofen) from next month as the drug is eligible for the national health insurance.
Peluvi is Korea’s 12th homegrown anti-inflammatory agent, which was developed as a result of intensive R&D efforts for seven years with 6 billion won investment.
Felubiprofen had already completed its phase I an...
Peluvi is Korea’s 12th homegrown anti-inflammatory agent, which was developed as a result of intensive R&D efforts for seven years with 6 billion won investment.
Felubiprofen had already completed its phase I an...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.